Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
Participation in JPMorgan Healthcare Conference
06
2025.01
Kangstem Biotech has been invited to participate in the J.P. Morgan Healthcare Conference 2025, which will be held in San Francisco, USA, from January 13th to 16th.
Kangstem Biotech has been invited to participate in the J.P. Morgan Healthcare Conference 2025, which will be held in San Francisco, USA, from January 13th to 16th. During the event, the company will hold independent partnering meetings with multinational pharmaceutical companies from the United States and Europe to discuss business opportunities related to osteoarthritis and atopic drugs, organoids, and more.
The market for osteoarthritis drugs is growing rapidly due to the increasing number of osteoarthritis patients, driven by the aging global population. In particular, there is a high demand for DMOAD that can regenerate cartilage, as current treatments only alleviate pain. In response, global pharmaceutical companies have turned their attention to OSCA, an advanced biofusion drug designed to treat knee osteoarthritis with a single injection, eliminating the need for surgery or procedures.
The head of Business Development at Kangstem Biotech stated, "After confirming our participation in the J.P. Morgan conference, we received the most inquiries and meeting requests for OSCA. Although it is still in the early stages, our Phase I clinical trials have confirmed its ability to not only control pain and improve joint function, but also regenerate cartilage and subchondral bone as seen through MRI-based image analysis." He continued, "Market analysis shows that companies with Phase II clinical trial data have secured the largest deals over the past four years. This underscores the importance of Phase II data in facilitating technology licensing to large pharmaceutical companies. Therefore, we will specifically discuss the Phase 2a clinical trial, which is scheduled to start at the beginning of the year, with the goal of securing statistical significance for Oscar, and secure a global big-deal partner based on the Phase 1 results, suggesting the potential for success in this trial.”
We will also meet with two of the world’s top pharmaceutical companies to discuss its next-generation pipeline, organoids. These companies are particularly interested in dermal organoids, which replicate the form and function of human skin. one global pharmaceutical company that requested a meeting said, "In line with the global trend to reduce animal testing, we aim to replace animal testing with skin organoids in atopic models.“
Additionally, a major U.S. pharmaceutical company has been receiving continuous updates on the development of hair follicle organoids for the past six months since BioEurope and has requested a face-to-face meeting at the conference. The company is in the process of investing in building an organoid portfolio. this meeting is expected to focus on the commercialization of hair follicle organoids, including how they might be used.